VERQUVO Drug Patent Profile

Which patents cover Verquvo, and when can generic versions of Verquvo launch?

Verquvo is a drug marketed by MSD and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fourteen patent family members in fifty countries.

The generic ingredient in VERQUVO is vericiguat. One supplier is listed for this compound. Additional details are available on the vericiguat profile page.

DrugPatentWatch^® Generic Entry Outlook for Verquvo

Verquvo was eligible for patent challenges on January 19, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 19, 2031. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (vericiguat), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for VERQUVO

International Patents:	214
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	52
Clinical Trials:	2
Patent Applications:	282
Drug Prices:	Drug price information for VERQUVO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VERQUVO
What excipients (inactive ingredients) are in VERQUVO?	VERQUVO excipients list
DailyMed Link:	VERQUVO at DailyMed

See drug prices for VERQUVO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VERQUVO

Constraining patent/regulatory exclusivity:

8,420,656

NDA:

214377

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VERQUVO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Merck Sharp & Dohme LLC	Phase 2
Johns Hopkins University	Phase 2
Josef Stehlik	Phase 4

See all VERQUVO clinical trials

Pharmacology for VERQUVO

Drug Class	Soluble Guanylate Cyclase Stimulator
Mechanism of Action	Guanylate Cyclase Stimulators

Paragraph IV (Patent) Challenges for VERQUVO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VERQUVO	Tablets	vericiguat	5 mg and 10 mg	214377	4	2025-01-21

US Patents and Regulatory Information for VERQUVO

VERQUVO is protected by six US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 8,420,656.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd	VERQUVO	vericiguat	TABLET;ORAL	214377-001	Jan 19, 2021		RX	Yes	No	9,993,476
Msd	VERQUVO	vericiguat	TABLET;ORAL	214377-003	Jan 19, 2021		RX	Yes	Yes	8,921,377
Msd	VERQUVO	vericiguat	TABLET;ORAL	214377-003	Jan 19, 2021		RX	Yes	Yes
Msd	VERQUVO	vericiguat	TABLET;ORAL	214377-001	Jan 19, 2021		RX	Yes	No
Msd	VERQUVO	vericiguat	TABLET;ORAL	214377-001	Jan 19, 2021		RX	Yes	No	11,439,642

EU/EMA Drug Approvals for VERQUVO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bayer AG	Verquvo	vericiguat	EMEA/H/C/005319Treatment of symptomatic chronic heart failure	Authorised	no	no	no	2021-07-16

International Patents for VERQUVO

When does loss-of-exclusivity occur for VERQUVO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cuba

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

France

Germany

Guatemala

Hong Kong

Hungary

Israel

Japan

Jordan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Morocco

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VERQUVO around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	081628	5-FLUORO-1H-PIRAZOLOPIRIDINAS SUSTITUIDAS Y SU USO
Australia	2011257335	Substituted 5-fluoro-1H-pyrazolopyridines and use thereof
Australia	2011257336	The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc).
Brazil	112012030010	5-flúor-1h-pirazolopiridinas substituídas e seu uso
Brazil	122020023470	PROCESSO PARA PREPARAÇÃO DE 5-FLÚOR-1H-PIRAZOLOPIRIDINAS SUBSTITUÍDAS

Supplementary Protection Certificates for VERQUVO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2576547	PA2021518	Lithuania		PRODUCT NAME: VERICIGUATAS IR JO DRUSKOS, SOLVATAI IR DRUSKU SOLVATAI ; REGISTRATION NO/DATE: EU/1/21/1561 20210716
2576547	CA 2021 00032	Denmark		PRODUCT NAME: VERICIGUAT OG DETS SALTE, SOLVATER OG SOLVATER AF SALTENE; REG. NO/DATE: EU/1/21/1561 20210720
2576547	LUC00221	Luxembourg		PRODUCT NAME: VERICIGUAT ET SES SELS, SOLVATES ET SOLVATES DES SELS; AUTHORISATION NUMBER AND DATE: EU/1/21/1561 20210720
2576547	122021000048	Germany		PRODUCT NAME: VERICIGUAT SOWIE DESSEN SALZE, SOLVATE UND SOLVATE DER SALZE; REGISTRATION NO/DATE: EU/1/21/1561 20210716
2576547	301146	Netherlands		PRODUCT NAME: VERICIGUAT; REGISTRATION NO/DATE: EU/1/21/1561 20210720

VERQUVO (vericiguat) Market Dynamics and Financial Trajectory (US and key ex-US uptake, pricing pressure, and exclusivity timeline)

Last updated: May 27, 2026

Verquvo (vericiguat) is a once-daily oral sGC stimulator positioned for chronic heart failure with reduced ejection fraction (HFrEF) and high-risk features. Post-launch, demand shifted toward guideline-adjacent “recent worsening heart failure” segments, with payer coverage tied to risk criteria and outcomes evidence from VICTORIA. Financial trajectory is shaped by (1) slow initial uptake typical for novel HFrEF therapies, (2) competitive pressure from foundational HFrEF regimens (ARNI/ACEi, beta blockers, MRAs, SGLT2 inhibitors), (3) formulary and prior-authorization constraints that narrow eligible populations, and (4) patent and exclusivity milestones that set expectations for generic entry after US exclusivity windows close.

---

How has VERQUVO (vericiguat) performed commercially and what revenue trajectory is implied by adoption patterns?

Core commercial signal: Uptake has generally been constrained by HFrEF guideline penetration, local payer policies, and the requirement for “recent worsening” and/or elevated natriuretic peptide markers used operationally to mirror VICTORIA-like eligibility.

What drives sales in HFrEF where multiple disease-modifying therapies overlap?

• VERQUVO is incremental to background mortality-reducing therapy. Its addressable pool is patients not at maximal benefit from existing regimens or those with persistent high-risk profiles after stabilization.
• SGLT2 inhibitors and ARNI are widely adopted across HFrEF, which reduces “marginal patients” for additional add-on therapy.
• The market’s prescribing behavior favors therapies with simpler eligibility and clear “plug-in” criteria; VERQUVO’s risk stratification introduces friction.

How do payer rules affect financial trajectory?

• Coverage policies often require documentation consistent with labeling, such as recent decompensation or high-risk biomarkers.
• Step edits and prior authorization delay initiation and reduce persistence, flattening quarter-to-quarter sales growth even when physicians accept the clinical value proposition.

Do sales show sensitivity to guideline updates?

• When guidelines emphasize “worsening despite standard therapy,” adoption improves because it matches the population most aligned with VICTORIA.
• When guideline emphasis shifts toward other add-ons or broader earlier intervention, VERQUVO’s incremental niche can narrow, slowing penetration.

---

What is the Orange Book status of VERQUVO and when do exclusivity and patent protections expire in the US?

Short answer (high intent): VERQUVO’s US IP moat is a combination of new chemical entity exclusivity and additional patent coverage for specific compositions and/or methods of use tied to vericiguat in heart failure indications. The practical outcome is a delayed ANDA/authorized generic path until relevant listed patents expire or are designed around.

What protections matter for generic entry risk?

• New chemical entity (NCE) exclusivity: Applies to the active ingredient vericiguat, preventing ANDA approval for a time window regardless of patent status.
• Listed Orange Book patents: Control when FDA can approve an ANDA/505(j) application challenging specific patents via Paragraph IV.
• Exclusivity layering: NCE exclusivity often runs alongside patent expiration, so generic risk is driven by whichever barrier ends last for the most relevant listed patents.

How to evaluate “real” launch timing for generics

• Use the latest of: (i) NCE/exclusivity end date, and (ii) expiration dates of the Orange Book patents most likely to be asserted against an ANDA.
• Settlement agreements from Paragraph IV litigations frequently move the actual launch date earlier than the theoretical latest barrier or later if brand leverages injunction risk.

Note: A complete Orange Book table with specific listed patent numbers and dates cannot be produced here without verifiable listing data in the cited record.

---

Which patents protect VERQUVO (vericiguat) and how strong is the patent estate for generic and biosimilar risk?

Vericiguat is a small-molecule drug, so biosimilar risk does not apply. The generic landscape is determined by the Orange Book patent matrix, including:

• composition-of-matter (drug substance and drug product),
• formulation or pharmaceutical composition patents,
• method-of-use or treatment patents for specific heart failure populations,
• and manufacturing or process patents.

How do method-of-use vs composition patents change design-around strategy?

• If composition patents dominate, generics must wait for expiration or pursue a full carve-out, which is usually not feasible for composition-of-matter.
• If method-of-use patents dominate, challengers may attempt labeling carve-outs while still launching a product for non-patented indications, creating “at-risk” launch dynamics.

What is the typical litigation posture in this class?

• Brand generally asserts multiple patents across composition and method-of-use, making early ANDA approval contingent on full resolution of the asserted set.
• If multiple patents remain unexpired, generic launch can be deferred even after settlement on one patent.

Note: No patent-number specific estate scoring can be provided without a source-backed Orange Book or litigation docket record.

---

What generic entry risks exist for VERQUVO under Paragraph IV challenges?

Market impact mechanism: Paragraph IV filings can compress expected future brand sales via:

• court timelines (brand uses litigation to delay),
• early settlement (brand pays to delay),
• or failure to settle (generic takes a launch lead if stays are not imposed or are lifted).

How does a successful Paragraph IV alter market dynamics?

• Entry triggers price competition, usually driving:
  • contracted net price declines,
  • channel stock reductions,
  • and increased rebate pressure to maintain formulary access.
• The first entrant’s penetration determines whether subsequent entrants accelerate losses.

How quickly do payers shift after launch?

• Shifts are often slower than headline launch because:
  • formulary committee cycles,
  • member-specific prior auth,
  • and ongoing clinical switching thresholds.

---

How does VERQUVO compare with competing HFrEF drugs in market positioning and pricing pressure?

Verquvo competes indirectly within HFrEF add-on therapy. The commercial “competition” is not a one-to-one substitution but a portfolio choice among disease-modifying therapies.

Key competitive sets

• Core mortality therapies: ARNI/ACEi, beta blockers, mineralocorticoid receptor antagonists (MRAs).
• Modern HFrEF disease modifiers: SGLT2 inhibitors.
• Other add-on pathways: iron deficiency management and other comorbidity-driven therapies.

What differentiates VERQUVO in formularies?

• It targets a high-risk cohort defined by recent worsening heart failure.
• It has a distinct prescribing trigger relative to SGLT2 inhibitors’ broader population adoption.
• That differentiation supports coverage in targeted patient groups, but it can cap scale if “recent worsening” criteria are applied narrowly.

Why does pricing pressure matter more than incremental clinical benefit?

• In HFrEF, payers negotiate for cost-effective benefit across multiple agents. When budgets tighten, payers may prefer the therapies with broader evidence coverage or higher baseline adoption.

---

What manufacturing and distribution constraints affect VERQUVO supply and financial outcomes?

For a single oral solid drug, constraints are typically:

• API and solid dose manufacturing capacity,
• stability and packaging logistics,
• and batch release performance tied to quality systems.

What could create revenue volatility even with steady demand?

• Supply interruptions causing delayed refill patterns.
• Increased costs from contract manufacturing changes.
• Quality events that trigger distribution holds.

No supply disruption facts can be asserted without a sourced operational record.

---

What FDA pathway and label scope shape VERQUVO commercial addressability?

Verquvo’s label scope is the core driver for eligible population size. Addressability is increased by broader eligibility criteria and reduced by narrow biomarker or “recent worsening” definitions.

How do label scope changes affect financial trajectory?

• Any label expansion can widen prescriber behavior and payer approval.
• Label tightening or restrictive payer interpretation reduces addressability even if clinical adoption exists.

No label-change event timeline can be enumerated here without sourced FDA label history.

---

Settlement and litigation: what patent disputes affect VERQUVO’s financial outlook?

The financial outlook is tied to:

• likelihood of generic launch timing,
• speed of resolution,
• and whether brand obtains stays or injunctions.

What litigation outcomes typically change most

• Start date for ANDA approval if stayed or lifted.
• Settlement terms that create agreed launch delays.
• Carve-outs affecting labeling and patient targeting.

No case-specific litigation schedule or settlement terms are provided because a verifiable docket record is not supplied in the prompt material.

---

Revenue sensitivity: how much of VERQUVO’s future depends on exclusivity windows and HFrEF segment size?

VERQUVO’s revenue trajectory is most sensitive to two variables:

1. Exclusivity end date and Orange Book patent status
   • Determines when pricing pressure begins through generic entry.
2. Share of HFrEF “high-risk recent worsening” segment
   • Determines how quickly physicians and payers scale usage once background therapy is established.

Scenario framework used by commercial planners (directional)

• Base case: Continued growth or stable share in targeted patients with moderate net price declines.
• Downside: Broader adoption of alternative add-ons or tighter payer restrictions compress eligible populations, reducing unit growth and increasing rebate pressure.
• Upside: Guideline alignment and label/application clarity expand eligible patients, improving persistence and lowering barriers.

---

Key Takeaways

• VERQUVO’s financial trajectory is driven by its targeted HFrEF risk niche and payer eligibility friction rather than broad substitution against foundational HFrEF regimens.
• Post-launch uptake is constrained by overlap with widely adopted mortality and disease-modifying therapies, especially SGLT2 inhibitors, reducing incremental patient pools.
• Exclusivity and Orange Book patent status determine the timing and magnitude of generic-driven pricing pressure.
• Patent litigation outcomes and settlements can materially change expected launch timing and therefore future revenue.

---

FAQs

1. What patient criteria most limit VERQUVO reimbursement in HFrEF?
2. How do generic launch timelines for VERQUVO differ between Paragraph IV settlements and no-settlement court outcomes?
3. What formulation or method-of-use patent types most commonly block ANDA design-arounds for VERQUVO?
4. How does VERQUVO net pricing typically respond when the first generic enters the market?
5. Which HFrEF guideline updates most influence VERQUVO prescribing and payer coverage decisions?

---

References (APA)

1. No citable sources were provided in the prompt.